Drug Profile
AVE 8134
Alternative Names: AVE8134Latest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator Genfit; sanofi-aventis
- Developer Sanofi; sanofi-aventis
- Class Antihyperglycaemics
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Heart failure; Lipid metabolism disorders; Type 2 diabetes mellitus
Most Recent Events
- 08 Sep 2021 Discontinued - Phase-II for Type 2 diabetes mellitus in Spain, Germany, Italy (PO) (EudraCT2005-005141-19)
- 04 Apr 2008 Discontinued - Phase-II for Congestive heart failure in France (unspecified route)
- 04 Apr 2008 Discontinued - Phase-II for Lipid metabolism disorders in France (unspecified route)